Education
About Us
Working with TipRanks
Follow Us
Venus Concept (VERO)
NASDAQ:VERO
VERO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.33 - $17.49
Previous CloseN/A
Volume97.51K
Average Volume (3M)102.62K
Market Cap
$1.81M
Enterprise Value$38.81M
Total Cash (Recent Filing)$5.40M
Total Debt (Recent Filing)$79.70M
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Mar 31, 2025EPS Estimate
-10.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-88.18
Shares Outstanding659,571
10 Day Avg. Volume85,715
30 Day Avg. Volume102,624
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.04
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap21.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda-1.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
Venus Concept News
PremiumCompany Announcements
Venus Concept Secures Funding Amid Executive Resignation
PremiumCompany Announcements
Venus Concept Secures Loan Amendment; Board Member Resigns---
Bulls Say, Bears Say
Bulls Say
International ExpansionThe company is reaching an inflection point in its international business, as VERO executes on its strategic shift towards increased reliance on distributors within these markets.
Product ApprovalsRecently, the company expanded its distribution network through new agreements in Asia and South America, received marketing clearance for Bliss MAX in Australia, as well as several products in India.
Resource AllocationVERO is focused on cash management and allocating its resources to high priority initiatives, such as R&D efforts for its next-gen body contouring system.
Bears Say
Debt ConcernsConcerns remain about the company's debt overhang and the prevailing aesthetic industry headwinds in the US.
Revenue PerformanceVERO’s significantly lower-than-expected 3Q24 revenue reflects persistent weakness in the US market, as well as company-specific issues.
Strategic UncertaintyThe trajectory of the strategic turnaround remains uncertain, and therefore, based on risk/reward analysis, there is no current recommendation for purchasing VERO shares.
---
Ownership Overview
8.01% Insiders
0.92% Mutual Funds
15.30% Other Institutional Investors
75.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VERO FAQ
What was Venus Concept’s price range in the past 12 months?
Venus Concept lowest stock price was $2.33 and its highest was $17.49 in the past 12 months.
What is Venus Concept’s market cap?
Venus Concept’s market cap is $1.81M.
When is Venus Concept’s upcoming earnings report date?
Venus Concept’s upcoming earnings report date is Mar 31, 2025 which is today.
How were Venus Concept’s earnings last quarter?
Venus Concept released its earnings results on Nov 13, 2024. The company reported -$14.08 earnings per share for the quarter, missing the consensus estimate of -$12.48 by -$1.6.
Is Venus Concept overvalued?
According to Wall Street analysts Venus Concept’s price is currently Overvalued.
Does Venus Concept pay dividends?
Venus Concept does not currently pay dividends.
What is Venus Concept’s EPS estimate?
Venus Concept’s EPS estimate is -10.01.
How many shares outstanding does Venus Concept have?
Venus Concept has 659,571 shares outstanding.
What happened to Venus Concept’s price movement after its last earnings report?
Venus Concept reported an EPS of -$14.08 in its last earnings report, missing expectations of -$12.48. Following the earnings report the stock price went down -10%.
Which hedge fund is a major shareholder of Venus Concept?
Currently, no hedge funds are holding shares in VERO
---
Company Description
Venus Concept
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
---
VERO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view. On the positive side, there were significant strategic achievements in reducing cash used and debt, as well as successful international restructuring and new product registrations. However, these were balanced by challenges in the U.S. market, overall revenue declines, and extended sales cycles due to macroeconomic headwinds.Read More>---
VERO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---